Salary: Grade E64: £31,931 - £51,176 p.a.
We are seeking a Clinical Researcher to join Professor Jack Satsangis group with an intention of delivering a research programme aimed at understanding the pathogenesis, and stratifying the care of patients with inflammatory bowel disease for biological therapy. The studies will be performed in the Translational Gastroenterology Unit, John Radcliffe site.
Building on previous work by the research group, and the IBD-BIOM and IBD-CHARACTER Consortia, the post holder will develop assays for epigenetic, proteomic, and glycomic biomarkers that predict the clinical course in inflammatory bowel disease, and also predict primary and secondary response/non-response to biological agents, including anti-TNF therapy and apply these in samples from patient cohorts. The post holder interacts with clinical and non-clinical scientists, and members of the biobanking teams and provides guidance to less experienced members of the research group, including postdocs, research assistants, technicians, and PhD and project students.
The post will suit either a clinician without a higher degree, to provide a basis for developing research skills before applying for a research training fellowship; or an experienced trainee with a higher degree nearing/ having reached accreditation who wishes to develop their knowledge in translational medicine, and apply for an intermediate fellowship, or academic positions. Opportunities are available for developing projects either in biomarker discovery, or in basic science, to understand the biological relevance of markers identified with a view to target discovery, with a series of collaborations in place.
The appointee will interact with clinicians and scientists across the campus in Oxford. Strong support will be given for developing further scientific work.
Applications for this vacancy are to be made online. You will be required to upload a supporting statement and CV as part of your online application.
Only applications received before 12.00 midday on 12th December 2018 will be considered.